News
ZURA
6.03
0.00%
0.00
Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver
Seeking Alpha · 4d ago
Weekly Report: what happened at ZURA last week (0323-0327)?
Weekly Report · 5d ago
Zura Bio management to meet with Piper Sandler
TipRanks · 03/23 20:25
Zura Bio Price Target Raised to $11.00/Share From $10.00 by Chardan Capital
Dow Jones · 03/23 12:10
Zura Bio Is Maintained at Buy by Chardan Capital
Dow Jones · 03/23 12:10
Weekly Report: what happened at ZURA last week (0316-0320)?
Weekly Report · 03/23 09:55
Zura Bio Price Target Cut to $15.00/Share From $16.00 by Oppenheimer
Dow Jones · 03/20 15:12
Zura Bio Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/20 15:12
Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15
Benzinga · 03/20 15:02
Wedbush Sticks to Their Buy Rating for Zura Bio (ZURA)
TipRanks · 03/20 13:16
ZURA BIO LIMITED <ZURA.O>: OPPENHEIMER CUTS TARGET PRICE TO $15 FROM $16
Reuters · 03/20 12:20
Zura Bio price target lowered to $15 from $16 at Oppenheimer
TipRanks · 03/20 11:41
U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedEx
Reuters · 03/20 06:50
Zura Bio's FY net loss widens on higher R&D costs
Reuters · 03/19 20:33
Zura Bio Q4 EPS $(0.49) Misses $(0.22) Estimate
Benzinga · 03/19 20:31
Zura Bio Reports 2025 Results, Extends Cash Runway Outlook
TipRanks · 03/19 20:31
Zura Bio GAAP EPS of -$1.06 misses by $0.31
Seeking Alpha · 03/19 20:29
Zura Bio reports FY25 EPS ($1.06) vs (60c) last year
TipRanks · 03/19 20:16
ZURA BIO REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES
Reuters · 03/19 20:05
Press Release: Zura Bio Reports Full Year 2025 -2-
Dow Jones · 03/19 20:05
More
Webull provides a variety of real-time ZURA stock news. You can receive the latest news about Zura Bio Limited through multiple platforms. This information may help you make smarter investment decisions.
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.